|
[1]
|
National Health Service (NHS) (2007) Exenatide. New Drug Evaluation, 84.
|
|
[2]
|
Centro Andaluz de Información de Medicamentos (CADIME) (2009) Exenatida (DCI). Ficha de Novedad Terapéutica 2.
|
|
[3]
|
Campoamor, F. (2008) Exenatida en la diabetes mellitus tipo 2. Comisión de Evaluación de Medicamentos, Islas Baleares.
|
|
[4]
|
Verzegnassi, F. and Chinello, M. (2010) Exenatide in Type 2 Diabetes. Lancet, 376, 1052-1053.
http://dx.doi.org/10.1016/S0140-6736(10)61485-7
|
|
[5]
|
Peters, A. (2010) Incretin-Based Therapies: Review of Current Clinical Trial Data. American Journal of Medicine, 123, S28-S37. http://dx.doi.org/10.1016/j.amjmed.2009.12.007
|
|
[6]
|
Wajcberg, E. and Tavaria, A. (2009) Exenatide: Clinical Aspects of the First Incretin-Mimetic for the Treatment of Type 2 Diabetes Mellitus. Expert Opinion on Pharmacotherapy, 10, 135-142.
http://dx.doi.org/10.1517/14656560802611832
|
|
[7]
|
Segal, J.B., Dy, S.M., Millman, E.A., Herbert, R., Bass, E.B. and Wu, A. (2007) Diffusion into Use of Exenatide for Glucose Control in Diabetes Mellitus: A Retrospective Cohort Study of a New Therapy. Clinical Therapeutics, 29, 1784-1794. http://dx.doi.org/10.1016/j.clinthera.2007.08.021
|
|
[8]
|
Philippe, J. (2009) Role and Indication of GLP-1 Analogues in the Treatment of Type 2 Diabetes. Revue Médicale Suisse, 5, 1260-1262, 1264-1265.
|
|
[9]
|
Reuter, H. and Erdmann, E. (2007) Exenatide—An Incretin-Mimetic Agent for the Treatment of Type 2 Diabetes Mellitus. Deutsche Medizinische Wochenschrift, 132, 571-574. http://dx.doi.org/10.1055/s-2007-970380
|
|
[10]
|
Gill, A., Hoogwerf, B.J., Burger, J., Bruce, S., Macconell, L., Yan, P., et al. (2010) Effect of Exenatide on Heart Rate and Blood Pressure in Subjects with Type 2 Diabetes Mellitus: A Double-Blind, Placebo-Controlled, Randomized Pilot Study. Cardiovascular Diabetology, 9, 6.
http://dx.doi.org/10.1186/1475-2840-9-6
|
|
[11]
|
Moretto, T.J., Milton, D.R., Ridge, T.D., Macconell, L.A., Okerson, T., Wolka, A.M., et al. (2008) Efficacy and Tolerability of Exenatidemonotherapy over 24 Weeks in Antidiabetic Drug-Naive Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. Clinical Therapeutics, 30, 1448-1460.
http://dx.doi.org/10.1016/j.clinthera.2008.08.006
|
|
[12]
|
Klonoff, D.C., Buse, J.B., Nielsen, L.L., Guan, X., Bowlus, C.L., Holcombe, J.H., et al. (2008) Exenatide Effects on Diabetes, Obesity, Cardiovascular Risk Factors and Hepatic Biomarkers in Patients with Type 2 Diabetes Treated for at Least 3 Years. Current Medical Research and Opinion, 24, 275-286.
|
|
[13]
|
Drucker, D.J., Buse, J.B., Taylor, K., Kendall, D.M., Trautmann, M., Zhuang, D., DURATION-1 Study Group, et al. (2008) Exenatide Once Weekly versus Twice Daily for the Treatment of Type 2 Diabetes: A Randomised, Open-Label, Non-Inferiority Study. Lancet, 372, 1240-1250.
http://dx.doi.org/10.1016/S0140-6736(08)61206-4
|
|
[14]
|
Okerson, T., Yan, P., Stonehouse, A., Brodows, R. and Bhole, D. (2008) Exenatide Improved Systolic Blood Pressure Compared to Insulin or Placebo in Patients with Type 2 Diabetes. Diabetologia, 51, S350.
|
|
[15]
|
Bergenstal, R., Kim, T., Yan, P., Darsow, T., Walsh, B., Okerson, T., et al. (2009) Exenatide Once Weekly Improved Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes during One Year of Treatment. Diabetes, 58, A43.
|
|
[16]
|
Bhushan, R., Elkind-Hirsch, K.E., Bhushan, M., Butler, W.J., Duncan, K. and Marrioneaux, O. (2009) Improved Glycemic Control and Reduction of Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes and Metabolic Syndrome Treated with Exenatide in a Clinical Practice Setting. Diabetes Technology & Therapeutics, 11, 353-359.
http://dx.doi.org/10.1089/dia.2008.0090
|
|
[17]
|
Kothare, P.A., Linnebjerg, H., Isaka, Y., Uenaka, K., Yamamura, A., Yeo, K.P., de la Peña, A., Teng, C.H., Mace, K., Fineman, M., Shigeta, H., Sakata, Y. and Irie, S. (2008) Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients with Type 2 Diabetes Mellitus. Journal of Clinical Pharmacology, 48, 1389-1399.
http://dx.doi.org/10.1177/0091270008323750
|
|
[18]
|
Linnebjerg, H., Kothare, P., Park, S., Mace, K. and Mitchell, M. (2009) The Effect of Exenatide on Lisinopril Pharmacodynamics and Pharmacokinetics in Patients with Hypertension. International Journal of Clinical Pharmacology and Therapeutics, 47, 651-658. http://dx.doi.org/10.5414/CPP47651
|
|
[19]
|
Menéndez Torre, E., Lafita Tejedor, J., Artola Menéndez, S., Millán Núñez-Cortés, J., Alonso García, á., Puig Domingo, M., García Solans, J.R., álvarez Guisasola, F., García Alegría, J., Mediavilla Bravo, J., Fernández-Santos, C.M. and Romero González, R. (2010) Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Avances en Diabetología, 26, 331-338. http://dx.doi.org/10.1016/S1134-3230(10)65006-5
|
|
[20]
|
Svec, F. (2010) Incretin Physiology and Its Role in Type 2 Diabetes Mellitus. Journal of the American Osteopathic Association, 110, eS20-eS24.
|
|
[21]
|
Sudhakaran, C., Fathima, M., Anjana, R.M., Unnikrishnan, R.I. and Mohan, V. (2010) Effectiveness of Exenatide in Asian Indians in a Clinical Care Setting. Diabetes Technology & Therapeutics, 12, 613-618.
http://dx.doi.org/10.1089/dia.2010.0033
|
|
[22]
|
Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K. and Trautmann, M. (2010) Once Weekly Exenatide Compared with Insulin Glargine Titrated to Target in Patients with Type 2 Diabetes (DURATION-3): An Open-Label Randomised Trial. Lancet, 375, 2234-2243.
http://dx.doi.org/10.1016/S0140-6736(10)60406-0
|
|
[23]
|
Bergenstal, R.M., Wysham, C., Macconell, L., Malloy, J., Walsh, B., Yan, P., Wilhelm, K., Malone, J., Porter, L.E. and DURATION-2 Study Group (2010) Efficacy and Safety of Exenatide Once Weekly versus Sitagliptin or Pioglitazone as an Adjunct to Metformin for Treatment of Type 2 Diabetes (DURATION-2): A Randomised Trial. Lancet, 376, 431-439. http://dx.doi.org/10.1016/S0140-6736(10)60590-9
|
|
[24]
|
Blevins, T., Han, J., Nicewarner, D., Chen, S., Oliveira, J.H. and Aronoff, S. (2010) Exenatide Is Non-Inferior to Insulin in Reducing HbA1c: An Integrated Analysis of 1423 Patients with Type 2 Diabetes. Postgraduate Medicine, 122, 118-128. http://dx.doi.org/10.3810/pgm.2010.05.2149
|
|
[25]
|
Natarajan, B., Edavalath, M., Davies, J., Jenkins, L., Marshall-Richards, N., Evans, D., Price, D.E. and Stephens, J.W. (2010) Clinical Experience with Exenatide in a Routine Secondary Care Diabetes Clinic. Primary Care Diabetes, 4, 57-60. http://dx.doi.org/10.1016/j.pcd.2009.11.001
|
|
[26]
|
Yoon, N.M., Cavaghan, M.K., Brunelle, R.L. and Roach, P. (2009) Exenatide Added to Insulin Therapy: A Retrospective Review of Clinical Practice over Two Years in an Academic Endocrinology Outpatient Setting. Clinical Therapeutics, 31, 1511-1523. http://dx.doi.org/10.1016/j.clinthera.2009.07.021
|
|
[27]
|
Drucker, D.J., Buse, J.B., Taylor, K., Kendall, D.M., Trautmann, M., Zhuang, D., Porter, L. and DURATION-1 Study Group (2008) Exenatide Once Weekly versus Twice Daily for the Treatment of Type 2 Diabetes: A Randomised, Open-Label, Non-Inferiority Study. Lancet, 372, 1240-1250. http://dx.doi.org/10.1016/S0140-6736(08)61206-4
|
|
[28]
|
Forti, A., Garcia, E.G., Yu, M.B., Jimenez, M.C., Brodows, R.G. and Oliveira, J.H. (2008) Efficacy and Safety of Exenatide Administered before the Two Largest Daily Meals of Latin American Patients with Type 2 Diabetes. Current Medical Research and Opinion, 24, 2437-2447.
http://dx.doi.org/10.1185/03007990802282398
|
|
[29]
|
Nyström, T., Gutniak, M.K., Zhang, Q., Zhang, F., Holst, J.J., Ahrén, B. and Sjöholm, Å. (2004) Effects of Glucagon-Like Peptide-1 on Endothelial Function in Type 2 Diabetes Patients with Stable Coronary Artery Disease. American Journal of Physiology-Endocrinology and Metabolism, 287, E1209-E1215.
http://dx.doi.org/10.1152/ajpendo.00237.2004
|
|
[30]
|
Thrainsdottir, I., Malmberg, K., Olsson, A., Gutniak, M. and Rydén, L. (2004) Initial Experience with GLP-1 Treatment on Metabolic Control and Myocardial Function in Patients with Type 2 Diabetes Mellitus and Heart Failure. Diabetes and Vascular Disease Research, 1, 40-43.
http://dx.doi.org/10.3132/dvdr.2004.005
|
|
[31]
|
Sokos, G.G., Nikolaidis, L.A., Mankad, S., Elahi, D. and Shannon, R.P. (2006) Glucagon-Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients with Chronic Heart Failure. Journal of Cardiac Failure, 12, 694-699.
http://dx.doi.org/10.1016/j.cardfail.2006.08.211
|
|
[32]
|
Bunck, M.C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R.M., Heine, R.J., et al. (2010) Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition. Diabetes Care, 33, 1734-1737. http://dx.doi.org/10.2337/dc09-2361
|
|
[33]
|
Buse, J.B., Bergenstal, R.M., Glass, L.C., Heilmann, C.R., Lewis, M.S., Kwan, A.Y., Hoogwerf, B.J. and Rosenstock, J. (2010) Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients with Type 2 Diabetes: A Randomized, Controlled Trial. Annals of Internal Medicine, 154, 1-12.
|
|
[34]
|
Kolterman, O.G., Buse, J.B., Fineman, M.S., Gaines, E., Heintz, S., Bicsak, T.A., Taylor, K., Kim, D., Aisporna, M., Wang, Y. and Baron, A.D. (2003) Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism, 88, 3082-3089.
http://dx.doi.org/10.1210/jc.2002-021545
|
|
[35]
|
Arnolds, S., Dellweg, S., Clair, J., Dain, M.P., Nauck, M.A., Rave, K. and Kapitza, C. (2010) Further Improvement in Postprandial Glucose Control with Addition of Exenatide or Sitagliptin to Combination Therapy with Insulin Glargine and Metformin: A Proof-of-Concept Study. Diabetes Care, 33, 1509-1515. http://dx.doi.org/10.2337/dc09-2191
|
|
[36]
|
Yoon, N.M., Cavaghan, M.K., Brunelle, R.L. and Roach, P. (2009) Exenatide Added to Insulin Therapy: A Retrospective Review of Clinical Practice over Two Years in an Academic Endocrinology Outpatient Setting. Clinical Therapeutics, 31, 1511-1523. http://dx.doi.org/10.1016/j.clinthera.2009.07.021
|
|
[37]
|
Sheffield, C.A., Kane, M.P., Busch, R.S., Bakst, G., Abelseth, J.M. and Hamilton, R.A. (2008) Safety and Efficacy of Exenatide in Combination with Insulin in Patients with Type 2 Diabetes Mellitus. Endocrine Practice, 14, 285-292.
http://dx.doi.org/10.4158/EP.14.3.285
|
|
[38]
|
Nayak, U.A., Govindan, J., Baskar, V., Kalupahana, D. and Singh, B.M. (2010) Exenatide Therapy in Insulin-Treated Type 2 Diabetes and Obesity. QJM, 103, 687-694.
http://dx.doi.org/10.1093/qjmed/hcq112
|
|
[39]
|
Nathan, D.M., Buse, J.B., Davidson, M.B., Heine, R.J., Holman, R.R., Sherwin, R., et al. (2006) Management of Hyperglycaemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 29, 1963-1972.
http://dx.doi.org/10.2337/dc06-9912
|
|
[40]
|
Schernthaner, G., Barnett, A.H., Betteridge, D.J., Carmena, R., Ceriello, A., Charbonnel, B., et al. (2010) Is the ADA/EASD Algorithm for the Management of Type 2 Diabetes (January 2009) Based on Evidence or Opinion? A Critical Analysis. Diabetologia, 53, 1258-1269.
http://dx.doi.org/10.1007/s00125-010-1702-3
|
|
[41]
|
German Diabetes Association, Matthaei, S., Bierwirth, R., Fritsche, A., Gallwitz, B., Häring, H.U., et al. (2009) Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus: Update of the Evidence-Based Guideline of the German Diabetes Association. Experimental and Clinical Endocrinology & Diabetes, 117, 522-557.
http://dx.doi.org/10.1055/s-0029-1239559
|
|
[42]
|
Apovian, C.M., Bergenstal, R.M., Cuddihy, R.M., Qu, Y., Lenox, S., Lewis, M.S., et al. (2010) Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes. American Journal of Medicine, 123, 468.e9-17.
|
|
[43]
|
Robles, G.I. and Singh-Franco, D. (2009) A Review of Exenatide as Adjunctive Therapy in Patients with Type 2 Diabetes. Drug Design, Development and Therapy, 3, 219-240.
http://dx.doi.org/10.2147/DDDT.S3321
|